Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
T47D Topotecan
0.1
Topo I
Chemotherapy
 -0.1220 0.17436
T47D Topotecan
0.31623
Topo I
Chemotherapy
 -0.2488 0.22376
T47D Topotecan
1.0
Topo I
Chemotherapy
 -0.2767 0.23309
T47D Topotecan
3.1623
Topo I
Chemotherapy
 -0.1971 0.22591
T47D Topotecan
10.0
Topo I
Chemotherapy
 -0.1726 0.15338
T47D Etoposide
0.0010833
Topo II
Chemotherapy
 1.0064 0.00033
T47D Etoposide
0.0033333
Topo II
Chemotherapy
 0.8502 0.00451
T47D Etoposide
0.01
Topo II
Chemotherapy
 0.9163 -0.00041
T47D Etoposide
0.031667
Topo II
Chemotherapy
 0.5953 0.01113
T47D Etoposide
0.1
Topo II
Chemotherapy
 0.1878 0.02231
T47D Etoposide
0.31623
Topo II
Chemotherapy
 -0.0459 0.03840
T47D Etoposide
1.0
Topo II
Chemotherapy
 -0.0220 0.07177
T47D Etoposide
3.1623
Topo II
Chemotherapy
 -0.1861 0.14904
T47D Etoposide
10.0
Topo II
Chemotherapy
 -0.1776 0.18272
T47D Dasatinib
0.001
BCR/ABL
MAPK/nRTK
 0.9372 0.00455
T47D Dasatinib
0.0031623
BCR/ABL
MAPK/nRTK
 0.9695 -0.00045
T47D Dasatinib
0.01
BCR/ABL
MAPK/nRTK
 0.9173 -0.00101
T47D Dasatinib
0.031623
BCR/ABL
MAPK/nRTK
 0.8910 0.00486
T47D Dasatinib
0.1
BCR/ABL
MAPK/nRTK
 0.8094 0.00409
T47D Dasatinib
0.31623
BCR/ABL
MAPK/nRTK
 0.7324 0.01639
T47D Dasatinib
1.0
BCR/ABL
MAPK/nRTK
 0.7403 0.01244
T47D Dasatinib
3.1623
BCR/ABL
MAPK/nRTK
 0.6769 0.01819
T47D Dasatinib
10.0
BCR/ABL
MAPK/nRTK
 0.4961 0.01864
T47D Trametinib
0.0001
MEK
MAPK/nRTK
 0.9279 0.00423
T47D Trametinib
0.00031623
MEK
MAPK/nRTK
 0.9443 0.00270